yue qiu

Mr. yue qiu

Macau University of Science and Technology, Macau, Macao
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GTGao Tu
Gao Tu
QLQing Liu
Qing Liu
YQyue qiu
yue qiu
ELElaine Leung
Elaine Leung
XYXiaojun Yao
Xiaojun Yao
Kirsten rat sarcoma viral oncogene homolog (KRAS) is a small GTPase protein which plays an important role in the treatment of KRAS mutant cancers. The FDA-approved AMG510 and MRTX849 (phase III clinical trials) are two potent KRASG12C-selective inhibitors that target KRAS G12C. However, the drug resistance caused by the second-site mutation in KRAS has emerged, and the mechanisms of drug resistance at atom level are still unclear. To clarify the mechanisms of drug resistance, we conducted long time molecular dynamics simulations (75 μs in total) to study the structural and energetic features of KRAS G12C and its four drug resistant variants to inhibitors. The combined binding free energy calculation and protein−ligand interaction fingerprint revealed that these second-site mutations indeed caused KRAS to produce different degrees of resistance to AMG510 and MRTX849. Furthermore, Markov State Models and 2D-free energy landscapes analysis revealed the difference in conformational changes of mutated KRAS bound with and without inhibitors. Furthermore, the comparative analysis of these systems showed that there were differences in their allosteric signal pathways. These findings provide the molecular mechanism of drug resistance, which helps to guide novel KRAS G12C inhibitor design to overcome drug resistance.

1 December 2009 in Transplantation Proceedings
Verified
Journal Article
Closed access
YQyue qiu
yue qiu
XZX. Zhu
X. Zhu
WWW. Wang
W. Wang
QXQ. Xu
Q. Xu
YDY. Ding
Y. Ding

26 December 2019 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
YQyue qiu
yue qiu
JHJia-Liang Hu
Jia-Liang Hu
CZChun-Cao Zhao
Chun-Cao Zhao
JZJi-Quan Zhang
Ji-Quan Zhang
FWFei Wu
Fei Wu
KRKe-Feng Ruan
Ke-Feng Ruan
Background. Gastroesophageal reflux disease (GERDs) is a common chronic digestive system disease, in which the symptoms of reflux esophagitis (RE) seriously affect the quality of life. Aims. We aimed to study the therapeutic effect of Zhujie Hewei granules (ZHG) on reflux esophagitis in model rats. Materials and Methods. A rat model of RE was established with the steps of half pylorus ligation, cardiotomy, and hydrochloric acid perfusion. The rats in treatment groups were orally administered with 1.30, 2.60, or 5.20 g/kg ZHG once daily for 28 days. Histopathological changes of the esophagus were observed with hematoxylin-eosin staining. The content of total bilirubin and pH in gastric juice was determined. Esophageal mucosal injury was assessed by macroscopic observation scores, mucosal injury index scores, and esophageal inflammation scores. The levels of gastrin (GAS), motilin (MTL), and vasoactive intestinal peptide (VIP) in serum were evaluated by using ELISA kits. Results. After treatment with ZHG, the body weight of RE rats tended to increase drastically, the macroscopic observation scores of the esophagus mucous membrane decreased (P<0.05), the mucosal injury index scores decreased (P<0.05), the gastric pH values increased (P<0.05), and the levels of serum MTL and VIP decreased (P<0.05). In addition, the high dose of the ZHG-treated group showed lower serum GAS (P<0.05), while the high and middle doses of the ZHG-treated groups showed lower esophageal inflammation scores (P<0.05). Conclusions. ZHG was effective in treating RE in rats due using mechanisms including improving the pH value of gastric contents, decreasing the gastrointestinal hormones (including GAS, MTL, and VIP), and improving the inflammatory damage.

Verified
Journal Article
Open access
PDF file
YQyue qiu
yue qiu
QLQing Liu
Qing Liu
GTGao Tu
Gao Tu
XYXiaojun Yao
Xiaojun Yao
In late 2019, a new coronavirus (CoV) caused the outbreak of a deadly respiratory disease, resulting in the COVID-19 pandemic. In view of the ongoing pandemic, there is an immediate need to find drugs to treat patients. SARS-CoV-2 papain-like cysteine protease (PLpro) not only plays an important role in the pathogenesis of the virus but is also a target protein for the development of inhibitor drugs. Therefore, to develop targeted inhibitors, it is necessary to analyse and verify PLpro sites and explore whether there are other cryptic binding pockets with better activity. In this study, first, we detected the site of the whole PLpro protein by sitemap of Schrödinger (version 2018), the cavity of LigBuilder V3, and DeepSite, and roughly judged the possible activated binding site area. Then, we used the mixed solvent dynamics simulation (MixMD) of probe molecules to induce conformational changes in the protein to find the possible cryptic active sites. Finally, the TRAPP method was used to predict the druggability of cryptic pockets and analyse the changes in the physicochemical properties of residues around these sites. This work will help promote the research of SARS-CoV-2 PLpro inhibitors.

13 September 2022 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
QLQing Liu
Qing Liu
MSMenghua Song
Menghua Song
YQyue qiu
yue qiu
ELElaine Lai-Han Leung
Elaine Lai-Han Leung
QHQiang Huang
Qiang Huang
XYXiaojun Yao
Xiaojun Yao
A major obstacle of the selective inhibitor design for specific human phosphodiesterase (PDE) is that highly conserved catalytic pockets are difficult to be distinguished by inhibitor molecules. To overcome this, a feasible path is to understand the molecular determinants underlying the selectivity of current inhibitors. BAY60-7550 (BAY for short; IC50 = 4.7 nM) is a highly selective inhibitor targeting PDE2A which is a dual-specificity PDE and an attractive target for therapeutic intervention of the central nervous system (CNS) disorders. Recent studies suggest that molecular determinants may be in binding processes of BAY. However, a detailed understanding of these processes are still lacking. To explore these processes, High-Throughput Molecular Dynamics (HTMD) simulations were performed to reproduce the spontaneous association of BAY with catalytic pockets of 4 PDE isoforms; Ligand Gaussian Accelerated Molecular Dynamics (LiGaMD) simulations were performed to reproduce the unbinding-rebinding processes of FKG and 10.13039/100016266 MC2 , two pyrazolopyrimidinone PDE2A selective inhibitors, in the PDE2A system. The produced molecular trajectories were analyzed by the Markov state model (MSM) and the molecular mechanics/generalized Born surface area (MM/GBSA). The results showed that the non-covalent interactions between the non-conserved residues and BAY, especially the hydrogen bonds, determined the unique binding pathways of BAY on the surface of PDE2A. These pathways were different from those of BAY on the surface of the other three PDE isoforms and the binding pathways of the other two PDE2A inhibitors in PDE2A systems. These differences were ultimately reflected in the high selectivity of this inhibitor for PDE2A. As a result, this study demonstrates the critical role of the binding processes in the selectivity of BAY, and also identifies the key non-conserved residues affecting the binding processes of BAY. Thus, this study provides a new perspective and data support for the further development of BAY-derived inhibitors targeting PDE2A.

19 September 2025 in The Journal of Physical Chemistry A
Verified
Journal Article
Closed access
YQyue qiu
yue qiu
WHWei Ling Hong
Wei Ling Hong
XWXiao Wang
Xiao Wang
CLCheng Pu Liao
Cheng Pu Liao
SJShi-Peng Jiang
Shi-Peng Jiang
HJHua-Juan Jiang
Hua-Juan Jiang